Ban Abortion by Mail Act
- Sponsor
- Rep. Biggs, Sheri [R-SC-3]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jun 24, 2026
Bottom line
The 'Ban Abortion by Mail Act' seeks to reinstate and expand federal restrictions on medication abortion by requiring in-person visits and state-specific provider licensing, potentially limiting access to mifepristone and other abortion drugs.
What it actually does
This bill prohibits healthcare providers certified under the Mifepristone Risk Evaluation and Mitigation Strategies (REMS) Program from prescribing, dispensing, or administering mifepristone or any other abortion drug without an in-person visit with the patient and without holding a medical license in the patient's state of residence. Violations would result in the loss of REMS-certified status for at least two years. It also mandates annual reporting to Congress by the Secretary of Health and Human Services on providers who lose their REMS status due to these violations or unsafe prescribing practices.
Proponents argue
Proponents argue that these requirements are essential for patient safety, ensuring that individuals receiving abortion drugs are closely monitored for adverse effects and receive care from a provider licensed in their state. They contend that the purpose of REMS is to ensure a drug's benefits outweigh its risks, especially for serious safety concerns, and that in-person visits and local licensing uphold this principle by providing necessary medical oversight and accountability.
Opponents contend
Opponents contend that this bill imposes medically unnecessary restrictions on medication abortion, creating significant barriers to care, particularly for patients in rural areas or those living in states with limited access to abortion providers. They argue that the FDA has already determined mifepristone is safe and effective for telehealth prescription and that these requirements are politically motivated attempts to restrict abortion access rather than genuine efforts to enhance patient safety, potentially forcing individuals to seek later-term surgical abortions or unsafe alternatives.
The bill is short and straightforward, making it highly accessible for a reader to understand its core provisions within a few minutes.
Section 3(a)
In-Person Visit Requirement for Abortion Drugs
This provision mandates that any healthcare provider certified under the Mifepristone REMS Program must conduct an in-person visit with a patient before prescribing, dispensing, or administering mifepristone or any other drug defined as an 'abortion drug'. If a provider knowingly violates this requirement, they will lose their REMS-certified status for that drug for a minimum of two years.
Supporters argue
Proponents argue that an in-person visit is crucial for patient safety, allowing providers to conduct necessary examinations, confirm pregnancy status, rule out ectopic pregnancies, and ensure the patient is fully informed and monitored for potential adverse effects, thereby aligning with the serious safety concerns associated with REMS drugs.
Critics contend
Opponents contend that requiring an in-person visit is medically unnecessary and creates significant barriers to care, especially for individuals in rural areas, those with limited transportation, or those seeking to maintain privacy. They point to FDA's previous decision to remove this requirement for mifepristone, citing evidence of its safety and efficacy when prescribed via telehealth.
Tradeoffs
This provision balances concerns over patient safety and direct medical oversight against patient access to care and the convenience of telehealth services. It also highlights the tension between federal regulatory authority (FDA's REMS program) and state-level medical practice regulations.
Section 3(b)
State Medical License Requirement for Abortion Drugs
This provision requires that any REMS-certified provider prescribing, dispensing, or administering mifepristone or any other abortion drug must hold a valid medical license in the specific state where the patient resides. A knowing violation of this rule would result in the provider losing their REMS-certified status for that drug for a minimum of two years.
Section 3(c)
Annual Reporting on Lost REMS-Certified Status
This provision mandates that the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, must submit an annual report to Congress. This report will list all REMS-certified providers who have lost their certification due to violations of this Act (i.e., failing to meet in-person visit or state licensing requirements) or due to improper or unsafe prescribing of mifepristone or any other abortion drug.
Section 3(d)(1)
Broad Definition of 'Abortion Drug'
This section defines 'abortion drug' broadly as any drug, substance, or combination intended or used to intentionally kill an unborn child or terminate a pregnancy, excluding uses for live birth, removing a dead unborn child, or treating an ectopic pregnancy. This definition is significant because the in-person visit and state licensing requirements apply not only to mifepristone but to any drug falling under this broad definition.
The definition of 'abortion drug' is broadly worded to include 'any drug, substance, or combination of drugs or substances that is intended for use or that is in fact used (irrespective of how the product is labeled) to intentionally kill the unborn child of a woman known to be pregnant, or to intentionally terminate the pregnancy of a woman known to be pregnant, with an intention other than to produce a live birth; to remove a dead unborn child; or to treat an ectopic pregnancy.'
Section 3(d)(1)
Why it matters:While definitions are typically placed in such sections, the breadth of this particular definition, especially the phrase 'irrespective of how the product is labeled,' suggests an intentional effort to cast a wide net, potentially beyond what a casual reader might assume is the bill's scope (i.e., just mifepristone).
Case for: Proponents argue this broad definition is necessary to prevent pharmaceutical companies or providers from re-labeling or re-purposing drugs to circumvent the in-person visit and state licensing requirements, ensuring that the safety measures apply consistently to all medications used for abortion.
Case against: Opponents contend that the definition is overly broad and vague, potentially encompassing drugs not primarily intended for abortion, leading to unintended restrictions on other medical treatments. They argue it could create legal uncertainty and administrative burdens for healthcare providers who might unknowingly fall under its purview.
Estimated impact: This definition could significantly expand the scope of the bill's restrictions beyond mifepristone to other medications, potentially impacting a wider range of reproductive health services and drugs.